(Q37873948)

24 August 2017

1 reference

title

Cetuximab in the treatment of patients with colorectal cancer (English)

1 reference

24 August 2017

0 references

1 reference

1 reference

Christopher R Garrett

series ordinal

1

1 reference

24 August 2017

Cathy Eng

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

11 May 2011

1 reference

Expert Opinion on Biological Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

937-949

1 reference

24 August 2017

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Declining death rates reflect progress against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

The biochemistry and physiology of the receptor-kinase for epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

The epidermal growth factor receptor as a target for colorectal cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N99

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Does Sunscreen Prevent Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash? Results of a Placebo-Controlled Trial from the North Central Cancer Treatment Group (N05C4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Cetuximab therapy and symptomatic hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Somatic mutations of EGFR in colorectal cancers and glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

EGFR FISH in colorectal cancer: what is the current reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Clinical significance of tumor suppressor PTEN in colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Cost considerations in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

The price tag on progress--chemotherapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.582464

10.1517/14712598.2011.582464

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference